Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, New York 10065, USA.
J Thorac Oncol. 2011 Nov;6(11):1849-56. doi: 10.1097/JTO.0b013e318227142d.
There is growing evidence that lung adenocarcinoma and squamous cell carcinoma (SQCC) have distinct oncogenic mutations and divergent therapeutic responses, which is driving the heightened emphasis on accurate pathologic subtyping of non-small cell lung carcinoma (NSCLC). The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction.
Concurrent biopsy and cytology specimens obtained during a single procedure and diagnosed as NSCLC during a 2-year period (n = 101) were reviewed. Concordance of diagnoses in the two methods was assessed. Accuracy was determined based on subsequent resection or autopsy diagnosis (n = 21) or IHC for thyroid transcription factor 1 and p63 on a subset of cases (n = 43).
The distribution of definitive versus favored versus unclassified categories (reflecting the degree of diagnostic certainty) was similar for biopsy (71% versus 23% versus 6%, respectively) and cytology (69% versus 19% versus 12%, respectively), p = 0.29. When results from paired specimens were combined, the rate of definitive diagnoses by at least one method was increased to 84% and the unclassified rate was decreased to 4%. NSCLC subtype concordance between biopsy and cytology was 93%. Kappa coefficient (95% confidence interval) for agreement between methods was 0.88 (0.60-0.89) for adenocarcinoma and 0.76 (0.63-0.89) for SQCC. In pairs with discordant diagnoses (n = 7) the correct tumor type was identified with a similar frequency by biopsy (n = 4) and cytology (n = 3). Factors contributing to mistyping were poor differentiation, necrosis, low cellularity, and lack of supporting IHC. All concordant diagnoses for which verification was available (n = 57) were correct. IHC was used more frequently to subtype NSCLC in biopsy than cytology (32% versus 6%; p = 0.0001).
Small biopsy and cytology achieve comparable rates of definitive and accurate NSCLC subtyping, and the optimal results are attained when the two modalities are considered jointly. The lower requirement for IHC in cytology highlights the strength of cytomorphology in NSCLC subtyping. Whenever clinically feasible, obtaining parallel biopsy and cytology specimens is encouraged.
越来越多的证据表明,肺腺癌和鳞状细胞癌(SQCC)具有不同的致癌突变和不同的治疗反应,这促使人们更加重视非小细胞肺癌(NSCLC)的准确病理亚型分类。通过小活检与细胞学来进行 NSCLC 亚型分类的相对可行性和准确性尚不确定,尤其是在目前普遍使用免疫组织化学(IHC)来辅助这种区分的情况下。
对 2 年内通过单次手术获得的小活检与细胞学标本(n = 101)进行回顾,这些标本均被诊断为 NSCLC。评估两种方法的诊断一致性。根据随后的切除或尸检诊断(n = 21)或对部分病例(n = 43)进行甲状腺转录因子 1 和 p63 的 IHC,来确定准确性。
明确诊断、倾向诊断和未分类诊断(反映诊断的确定性程度)的分布在活检(分别为 71%、23%和 6%)和细胞学(分别为 69%、19%和 12%)中相似,p = 0.29。当结合配对标本的结果时,至少有一种方法的明确诊断率提高到 84%,未分类率降低至 4%。小活检与细胞学的 NSCLC 亚型一致性为 93%。方法之间的一致性的kappa 系数(95%置信区间)为腺癌 0.88(0.60-0.89),SQCC 为 0.76(0.63-0.89)。在诊断不一致的 7 对标本中(n = 7),通过活检(n = 4)和细胞学(n = 3)检测正确肿瘤类型的频率相似。导致误分类的因素是分化差、坏死、细胞数量少和缺乏支持性 IHC。所有可验证的一致诊断(n = 57)均正确。活检比细胞学更常使用 IHC 来进行 NSCLC 亚型分类(32%比 6%;p = 0.0001)。
小活检和细胞学都能达到明确和准确的 NSCLC 亚型分类的相似比例,并且当两种方法联合使用时可以达到最佳结果。细胞学中 IHC 的需求较低,突出了细胞形态学在 NSCLC 亚型分类中的优势。只要临床可行,鼓励同时获取小活检和细胞学标本。